Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Ligand Pharmaceuticals Inc

NASDAQ: LGND · Life Sciences · 11 alerts · CIK 886163

Share price
$301.71Close, Nov 16
Market cap
$6.04B
Shares outstanding
20MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Ligand Pharmaceuticals Inc filings on SEC EDGAR ↗

7:09 AM ET 8-K
M&A Deal

Ligand Pharmaceuticals Signs $23M M&A Deal with Sydnexis, Inc.

Ligand Pharmaceuticals acquired royalty and milestone payment rights for Ryjunea from Sydnexis for $23 million upfront. Ryjunea is a treatment for pediatric myopia licensed to Santen Pharmaceutical in the EMEA region, where it is already approved. Ligand will receive tiered royalties ranging from low-double-digits to high-teens on net sales in those territories.

Value
$23M
Counterparty
Sydnexis, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.